Note: Sample below may appear distorted but all corresponding word document files contain proper formattingExcerpt from Essay:
The researcher was able to pull up information on Venous Thromboembolism hospitalizations by utilizing ICD-10 (Maynard & Stein, 2010)
The clinical diagnosis of Venous Thromboembolism is defective; people that are suffering with signs and symptoms of Venous Thromboembolism, just 20% have thrombosis confirmed by diagnostic testing.13Clinical prediction rules have been developed to improve the probability of an accurate diagnosis. The most widely used model classifies patients into a high, moderate, or low probability of deep vein thrombosis (Maynard & Stein, 2010). When joined with research laboratory and radiological imaging tests, this method is superior to the old-style method of executing a diagnostic test in all patients with suspected Venous Thromboembolism (Martinez- 2008).
Prognosis, broken down by risk groups
A lot of the Deep Vein Thrombosis is occult and most of the time resolves instinctively without there being a problem. The main longstanding illness from Deep Vein Thrombosis is PTS, which confuses something like half of cases of symptomatic proximal Deep Vein Thrombosis; a lot of these cases start developing in 2 years later. Demise from Deep Vein Thrombosis is credited to enormous Pulmonary embolism, which causes something like 400,000 deaths that occur every year in the United States. (Maynard & Stein, 2010) Pulmonary embolism is the leading aim of preventable in-hospital death. The Longitudinal Investigation of Thromboembolism Etiology (LITE) that combined statistics from two potential cohort investigations, the research determined that the incidence of symptomatic Deep Vein Thrombosis and Pulmonary embolism in 30,680 members that were aged 45 years and much or older that had been trailed for 8 years. (Hyers, 2007)
Incidence and prevalence, trends, broken down by risk groups
Patients greater than the age of 40 are at an increased risk of Deep Vein Thrombosis when they are compared with patients that are much patients, with the danger going up twice as much after every decade (Hyers, 2007). There is much more proof that talks about how age plays a big part in the risk factor for Deep Vein Thrombosis. In one particular study, it was discovered that the incidence of Deep Vein Thrombosis went up when the person got older, getting >1% in patients >75 years of age. In the study, it documented that the incidence of pulmonary embolism as a proportion of total V Deep Vein Thrombosis also went up when the person aged. Some data that came from the prophylaxis of Deep Vein Thrombosis in medical patients confirmed that age >75 years is an free risk factor for Deep Vein Thrombosis in patients put in the hospital with an illness that was acute medical.3
The connection that was among obesity and Deep Vein Thrombosis is still being investigated by researcher. An association between obesity (frequently described as body mass index [BMI] >30 kg/m2) and Deep Vein Thrombosis has been established in reports for instance the SIRIUS report. (Maynard & Stein, 2010) in addition, patients older than 65 years of age who had experienced complete hip arthroplasty, a BMI of ?25 displayed that it was linked with a 2.5-fold escalation in re-hospitalization for Deep Vein Thrombosis (Yokoyama, 2012).41 on the other hand, other studies made discoveries that discovered that obesity is not necessarily an independent risk factor for Deep Vein Thrombosis.
There have been a lot of greater efforts which are necessary to increase awareness of Venous Thromboembolism and advance standards of Deep Vein Thrombosis deterrence in healthcare organizations. Most people according to the information mentioned are at risk for thrombosis, nevertheless some people are more at risk than others. It is obvious that those that go up under the knife or have some sort of surgery are even at a greater risk of developing Deep Vein Thrombosis.
Altom, L.K., Deierhoi, R.J., Grams, J., Richman, J.S., Vick, C.C., Henderson, W.G., . . . Hawn, M.T. (2012). Association between surgical care improvement program venous thromboembolism measures and postoperative events. The American Journal of Surgery, 204(5), 591-7.
Amin, a., Spyropoulos, a.C., Dobesh, P., Shorr, a., Hussein, M., Mozaffari, E., & Benner, J.S. (2010). Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). Journal of Thrombosis and Thrombolysis, 29(3), 326-39.
Angchaisuksiri, P., Atichartakarn, V., Aryurachai, K., Archararit, N., Rachakom, B., Atamasirikul, K., & Tiraganjana, a. (2007). Risk factors of venous thromboembolism in thai patients. International Journal of Hematology, 86(5), 397-402.
Ashrani, a.A., Silverstein, M.D., Rooke, T.W., Lahr, B.D., Petterson, T.M., Bailey, K.R., . . . Heit, J.A. (2010). Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study. Vascular Medicine, 15(5), 387-97.
Aujesky, D., Long, J.A., Fine, M.J., & Ibrahim, S.A. (2007). African-American race was associated with an increased risk of complications following venous thromboembolism. Journal of Clinical Epidemiology, 60(4), 410-6.
Baglin, T., Luddington, R., Brown, K., & Baglin, C. (2003). Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. The Lancet, 362(9383), 523-6.
Barnes, G.D., Birkmeyer, N., Flanders, S.A., Froehlich, J.B., Hemmila, M., Henke, P.K., . . . Share, D. (2012). Venous thromboembolism: A collaborative quality improvement model for practitioners, hospitals, and insurers. Journal of Thrombosis and Thrombolysis, 33(3), 274-9.
Caprini, J.A., Arcelus, J., Sehgal, L.R., Cohen, E.B., & Reyna, J.J. (2002). The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. International Angiology, 21(1), 78-85.
Duran, a., Sengupta, N., Diamantopoulos, a., Forster, F., Kwong, L., & Lees, M. (2012). Cost effectiveness of rivaroxaban vs. enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective. PharmacoEconomics, 30(2), 87-101.
Farmer, R.D.T., Newson, R.B., MacRae, K., Lawrenson, R.A., & Tyrer, F. (1997). Mortality from venous thromboembolism among young women in europe: No evidence for any effect of third generation oral contraceptives. Journal of Epidemiology and Community Health, 51(6), 630-5.
Folsom, a.R., Cushman, M., Heckbert, S.R., Rosamond, W.D., & Aleksic, N. (2003). Prospective study of fibrinolytic markers and venous thromboembolism. Journal of Clinical Epidemiology, 56(6), 598-603.
Freeman, a.L. (2010). Prevention of venous thromboembolism in obesity. Expert Review of Cardiovascular Therapy, 8(12), 1711-21.
Ghanim, a.J., Daskalakis, C., Eschelman, D.J., & Kraft, W.K. (2007). A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. Journal of Thrombosis and Thrombolysis, 24(3), 247-54.
Gross, C.P., Galusha, DH, & Krumholz, H.M. (2007). The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. Journal of General Internal Medicine, 22(3), 321-6.
Heit, J.A. (2003). The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism*. Chest, 124(3), 40S-8S.
Hitos, K., & Fletcher, J.P. (2006). Venous thromboembolism following primary total knee arthroplasty. International Angiology, 25(4), 343-51.
Huo, M.H., & Spyropoulos, a.C. (2011). The eighth american college of chest physicians guidelines on venous thromboembolism prevention: Implications for hospital prophylaxis strategies. Journal of Thrombosis and Thrombolysis, 31(2), 196-208.
Hurewitz, a.N., Khan, S.U., Groth, M.L., Patrick, P.A., & Brand, D.A. (2011). Dosing of unfractionated heparin in obese patients with venous thromboembolism. Journal of General Internal Medicine, 26(5), 487-91.
Hyers, T.M., & Spyropoulos, a.C. (2007). Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. Journal of Thrombosis and Thrombolysis, 24(3), 225-32.
Lamberg, a.L., Horvath-puho, E., Christensen, S., & Sorensen,, H.T. (2010). Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study. Osteoporosis International, 21(11), 1911-7.
Martinez-Gonzalez, J., Vila, L., & Rodriguez, C. (2008). Bemiparin: Second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Review of Cardiovascular Therapy, 6(6), 793-802.
Maynard, G., & Stein, J. (2010). Designing and implementing effective venous thromboembolism prevention protocols: Lessons from collaborative efforts. Journal of Thrombosis and Thrombolysis, 29(2), 159-66.
Michota, F.A. (2007). Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: The quality improvement process. Journal of General Internal Medicine, 22(12), 1762-70.
Osborne, N.H., M.D., Wakefield, T.W., M.D., & Henke, P.K., M.D. (2008). Venous thromboembolism in cancer patients undergoing major surgery. Annals of Surgical Oncology, 15(12), 3567-78.
Otrock, Z.K., Taher, a.T., Shamseddeen, W.A., Zaatari, G., Bazarbachi, a., & Mahfouz, R.A. (2008). Factor V HR2 haplotype: A risk factor for venous thromboembolism in individuals with absence of factor V leiden. Annals of Hematology, 87(12), 1013-6.
Raftopoulos, I., Martindale, C., Cronin, a., & Steinberg, J. (2008). The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: A prospective comparison trial. Surgical Endoscopy, 22(11), 2384-91.
Rathbun, S. (2008). Venous thromboembolism in women. Vascular Medicine, 13(3), 255-66.
Reeves, D., & Liu, C.Y. (2010). Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. Journal of Oncology Pharmacy Practice, 16(1), 27-31.
Sasaki, S., Miyakoshi, N., Matsuura, H., Saito, H., Nakanishi, T., Kudo, Y., . . . Shimada, Y. (2011). Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science, 16(1), 64-70.
Sasaki, S., Miyakoshi, N., Matsuura, H., Saitoh, H., Kudoh,…[continue]
"Venous Thromboembolism Vte In USA" (2013, February 14) Retrieved December 5, 2016, from http://www.paperdue.com/essay/venous-thromboembolism-vte-in-usa-85926
"Venous Thromboembolism Vte In USA" 14 February 2013. Web.5 December. 2016. <http://www.paperdue.com/essay/venous-thromboembolism-vte-in-usa-85926>
"Venous Thromboembolism Vte In USA", 14 February 2013, Accessed.5 December. 2016, http://www.paperdue.com/essay/venous-thromboembolism-vte-in-usa-85926
Bmj.com/cgi/content/full/325/7369/887 Pfizer, 'NEW FRAGMIN INDICATION FIGHTS SECOND LEADING CAUSE of DEATH in CANCER PATIENTS, CANCER-ASSOCIATED THROMBOSIS', retrieved feb 29th 2008, from, http://www.pfizer.ca/english/newsroom/press%20releases/default.asp?s=1&releaseID=160 Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove a, Lemmens J, Vermeulen P. (2002), 'Plasma fibrin D-dimer levels correlate with tumor volume, progression rate and survival in patients with metastatic Breast Cancer', British Journal of Cancer, http://www.ncbi.nlm.nih.gov/pubmed/11875705 John a Heit, (Sep 2005), "Cancer and Venous Thromboembolism: Scope of the Problem', Cancer